联合注射后编码B细胞和T细胞免疫原的新型冠状病毒DNA疫苗的免疫原性
Immunogenicity of DNA Vaccines against COVID-19 That Encode B- and T-Cell Immunogens after Combined Injection.
作者信息
Borgoyakova M B, Rudometov A P, Starostina E V, Zadorozhny A M, Tigeeva E V, Yakovlev V A, Kisakov D N, Kisakova L A, Karpenko L I, Ilyichev A A
机构信息
State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, , Novosibirsk region, Russia.
出版信息
Bull Exp Biol Med. 2025 Aug 29. doi: 10.1007/s10517-025-06461-4.
The possibility of enhancing the immune response to a DNA vaccine encoding an artificial polyepitope T-cell immunogen containing a large number of conserved epitopes from different proteins of SARS-CoV-2 virus (pBSI-COV-Ub) was assessed by additional introduction of a plasmid encoding the secreted receptor-binding domain of the of SARS-CoV-2 S protein (pVAXrbd). Both a specific humoral response and a cellular response of broad specificity were observed in animals co-injected with pBSI-COV-Ub and pVAXrbd. This indicates the potential of this approach as a vaccine strategy.
通过额外引入编码严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒S蛋白分泌型受体结合域的质粒（pVAXrbd），评估了增强对编码人工多表位T细胞免疫原的DNA疫苗（pBSI-COV-Ub）免疫反应的可能性，该免疫原包含来自SARS-CoV-2病毒不同蛋白的大量保守表位。在共同注射pBSI-COV-Ub和pVAXrbd的动物中观察到了特异性体液反应和广泛特异性的细胞反应。这表明这种方法作为一种疫苗策略具有潜力。
Zotero 插件